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Background: Despite the easy accessibility and diagnostic utility of PBMCs and their potential to show distinct
expression patterns associated with the accelerated disease progression in HIV/HCV co-infection, there has not been
a systematic study focusing on the global dysregulations of the biological pathways in PBMCs from HIV, HCV
mono- and co-infected individuals. This study aimed at identifying the transcriptome distinctions of PBMCs between
these patient groups.
Methods: Genome-wide transcriptomes of PBMCs from 10 HIV/HCV co-infected patients, 7 HIV+ patients, 5 HCV+
patients, and 5 HIV/HCV sero-negative healthy controls were analyzed using Illumina microarray. Pairwise comparisons
were performed to identify differentially expressed genes (DEGs), followed by gene set enrichment analysis (GSEA) to
detect the global dysregulations of the biological pathways between HIV, HCV mono- and co-infection.
Results: Forty-one, 262, and 44 DEGs with fold change > 1.5 and FDR (false discovery rate) <0.05 for the comparisons
of HCV versus co-infection, HIV versus co-infection, and HIV versus HCV were identified, respectively. Significantly altered
pathways (FDR < 0.05), featured by those involved in immune system, signaling transduction, and cell cycle, were
detected. Notably, the differential regulation of cytotoxicity pathway discriminated between HIV, HCV mono- and
co-infection (up-regulated in the former versus the latter group: co-infection versus HIV or HCV, HIV versus HCV;
FDR <0.001 ~ 0.019). Conversely, the cytokine-cytokine receptor interaction pathway was down-regulated in
co-infection versus either HCV (FDR = 0.003) or HIV (FDR = 0.028). For the comparison of HIV versus HCV, the cell cycle
(FDR = 0.016) and WNT signaling (FDR = 0.006) pathways were up- and down-regulated in HIV, respectively.
Conclusions: Our study is the first to identify the differential regulation of cytotoxicity pathway discriminating between
HIV, HCV mono- and co-infection, which may reflect the distinct patterns of virus-host cell interactions underlying
disease progression. Further inspection of cytotoxicity pathway has pinned down to the expression of the KIR genes to
be associated with specific patterns of particular virus-host interactions. Between HIV and HCV, the altered cell cycle
and WNT signaling pathways may suggest the different impact of HIV and HCV on cell proliferation and differentiation.
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Infection by HIV is commonly complicated by co-infection
with hepatitis C virus (HCV) due to shared routes of trans-
mission. Overall, about 30% of HIV-infected individuals
are co-infected with HCV in the United States and Europe
[1]. While AIDS-associated mortality has declined sub-
stantially [2] following the release of highly active anti-
retroviral therapy (HAART), HCV-related liver disease
has become the leading cause of death in HIV-infected in-
dividuals [2,3].
In co-infected individuals, HIV worsens the course of
HCV infection and vice versa. Liver fibrosis progresses
more rapidly in those patients than in mono-infected
ones, resulting in increased rates of cirrhosis and compli-
cations such as decompensation and hepatocellular car-
cinoma (HCC) [4-7]. Compared to HCV mono-infected
patients, co-infected individuals are also less likely to
achieve viral clearance, and have higher HCV viral loads
and more frequent HCV relapses after anti-HCV therapy
[8-11]. Similarly, the possible role of HCV to accelerate
HIV disease progression has also been reported by previ-
ous studies, which have shown the impaired CD4+ T cell
count recovery during HAART, higher risk of AIDS, and
liver disease-related deaths in co-infected individuals in
comparison to HIV mono-infected ones [12-19]. More-
over, adverse drug reactions to HAART such as rash and
hepatoxicity in HIV patients are exacerbated in co-
infected patients, making the virological control of HIV
harder to achieve [20-24].
Despite the clinical significance of HIV/HCV co-
infection, the mechanisms underlying the accelerated
progression of the diseases in the co-infected patients re-
main elusive. Using techniques such as real-time PCR and
microarray, gene expression profiling has provided a
unique opportunity for understanding virus-host interac-
tions at the transcriptional level. Research by PCR and
multiplex assays has revealed that in co-infected versus
mono-infected individuals, the former had decreased
levels of inflammatory cytokines (IL4, IL8, IL10, IL12,
TNF-α, and IFN-γ), increased levels of TGF-β [25,26], im-
paired response to IFN-α [27], and the association of IFN-
γ production with CD4+ T cell counts [25,28]. While PCR
studies mainly focused on cytokines, microarray analyses
enabled a genome-wide view of transcriptome dysregula-
tions by showing a range of important biological themes
associated with the co-infection, including aberrant im-
mune activation, regulation, and differentiation, impaired
innate immunity, and dysfunctions of NK and dendritic
cells in liver biopsies and PBMCs from co-infected pa-
tients [29,30]. Recently, two studies have also demon-
strated the dysregulation of cell cycle and metabolism in T
cell subsets from co-infected individuals [31,32].
In contrast, studies on the transcriptome of periph-
eral blood mononuclear cells (PBMCs) from HIV/HCVco-infection are limited despite their easy accessibility and
diagnostic utility in clinical settings. To date, only two
studies have focused on transcriptomes of PBMCs from
HIV, HCV mono- and co-infected individuals [29,30].
While the study by Rasmussen et al. has compared the
transcriptomes of PBMCs only between HCV infected
versus HCV and HIV co-infected individuals, the analysis
by Kottilil et al. has centered on gene clusters based on
differentially expressed genes (DEGs). However, neither of
them has looked into the global dysregulations of the bio-
logical pathways in PBMCs between HIV, HCV mono-
and co-infected individuals. In view of the easy accessibil-
ity and diagnostic utility of PBMCs and their potential to
show distinct expression patterns associated with the HIV
and/or HCV-host cell interactions underlying disease pro-
gression, this research studied the transcriptomes of
PBMCs from HIV+ patients (HIV; n = 7), HCV+ patients
(HCV; n = 5) and HIV/HCV co-infected patients (HH;
n = 10) along with HIV/HCV sero-negative healthy controls
(CTR; n = 5; Additional file 1). Focusing on significantly
altered KEGG pathways detected by gene set enrichment
analysis (GSEA), our analysis has shown for the first time,
the significant alterations of cytotoxicity pathway diffe-
rentiating between HIV, HCV mono- and co-infection
in PBMC transcriptome profiling. In HH versus HIV or
HCV, the down-regulation of cytokine-cytokine receptor
interaction and up-regulation of metabolic pathways clearly
indicated aberrant immune activation and more severely
perturbed metabolism in co-infection. Between HIV and
HCV mono-infection, the cell cycle and WNT pathways
were differentially regulated, which may implicate the dis-
tinct impact of HIV and HCV on cell proliferation.
Results
Identification of differentially expressed genes
Genome-wide transcriptomes of PBMCs from four study
groups including HIV, HCV mono- and co-infection along
with healthy controls (referred to as HIV, HCV, HH, and
CTR, respectively; Additional file 1) were analyzed using
Illumina microarray. Each patient group was compared to
the healthy controls and 2605, 2839, and 2260 differen-
tially expressed genes (DEGs) with False Discovery Rate <
0.05 (FDR < 0.05; FDR is a widely used statistical method
for multiple test correction) and fold change >1.5 in HH,
HIV, and HCV were detected, respectively (Additional
file 2). The DEGs present across the comparisons clearly
segregated all the patients from controls as demonstrated
by the heatmap (Figure 1). As our major goal was to inves-
tigate the transcriptome distinctions between mono- and
co-infected groups, our subsequent analysis focused on
direct comparisons between them.
For the pairwise comparisons of HCV versus HH, HIV
versus HCV, and HIV versus HH, 41, 44, and 262 DEGs,
respectively, with FDR < 0.05 and fold change >1.5 were
Figure 1 Heatmap for the differentially expressed genes separating controls from infected patients. Each row represents a gene and
each column represents a sample. The top 50 down- and up-regulated genes (FDR < 0.05; Additional file 2) common in HH, HIV, and HCV versus
healthy controls are shown. Red indicates higher expression and green indicates lower expression. Controls: ctrl1-5; HIV+ patients: HIV1-7; HIV/
HCV co-infected patients: coinfec1-10; HCV+ patients: HCV1-5.
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sification of the DEGs based on the biological process
from gene ontology (GO) revealed that developmental,
immune system, and metabolic processes were the major
biological themes across these DEG lists. For example,between HCV and HH, 15 out of 41 DEGs played important
roles in development and metabolism (WNT7A, CDKN1A,
CDKN1B, DUSP2, EGR2, FOS, ISYNA1, MCM2, NR4A1,
PAK1IP1, PRKACG, PTGS2, RGS2, SOX30, and XRN2)
and 3 DEGs were directly involved in the immune system
Table 1 Number of differentially expressed genes (DEGs;
fold change > 1.5 and FDR < 0.05) and differentially
regulated KEGG pathways (FDR < 0.05) derived from
pairwise comparisons between patients groups
HIVvsHH HCVvsHH HIVvsHCV
DEGs Up-regulated 188 35 18
Down-regulated 74 6 26
Total 262 41 44
KEGG pathways Up-regulated 13 6 17
Down-regulated 12 21 1
Total 25 27 18
Up-regulated and down-regulated in the former group; vs: versus.
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out of 44 DEGs were involved in development and metabol-
ism (ADAP2, FOXC1, HIPK2, HMGB2, ISYNA1, KDSR,
KIF5C, MCM2, MRPL39, ODC1, PDE3B, PLS1, PRKACG,
QTRTD1, RPS6KA3, SLC35A2, SOX30, TATDN3, TERF1,
and ZNF507). Between HIV and HH, 12 DEGs were in-
volved in the immune system (CAMLG, CD99L2, CLIC4,
CNIH, FPR3, HIATL1, HLA-DPB1, IKBKB, IL6, KLF10,
NLRP3, and OSM), and 102 out of 262 DEGs were engaged
in development and metabolism. These 102 DEGs included
critical genes in cell cycle (e.g. CDKN1A and CDKN2C),
genes encoding for transcription factors (e.g. NFATC3 and
FOXC1), growth factors (e.g. EGR2), and solute carriers (e.g.
SLC25A26).
Pathway analysis by GSEA
The GSEA revealed that for the pairwise comparisons of
HIV versus HH, HIV versus HCV, and HCV versus HH,
25, 18, and 27 pathways were significantly regulated, re-
spectively (FDR < 0.05; Table 1; Additional file 4). The
significant pathways detected in each comparison could
all be divided into five biological themes, including (1)
immune system; (2) signaling transduction and cell
cycle; (3) metabolism; (4) genetic information process-
ing; and (5) human diseases.
For the immune system, the innate immune related
pathways including Toll signaling, IgA production, anti-
gen processing and presentation pathways as well as
cytokine-cytokine receptor interaction, were significantly
altered in 2 of the 3 pairwise comparisons (Additional
file 4). Moreover, natural killer (NK) cell mediated cyto-
toxicity pathway was significantly altered in all the com-
parisons (up-regulated in HH versus HIV or HCV and
in HIV versus HCV, FDR from <0.001 to 0.019; Table 2).
For the signaling transduction and cell cycle, notable
was the significant up-regulation of p53 pathway in HIV
versus HH (FDR = 0.029) as well as the dysregulation of
WNT signaling (up-regulated in HCV, FDR = 0.006) and
cell cycle (down-regulated in HCV, FDR = 0.016) path-
ways between HIV and HCV.For the metabolism, a range of pathways were found to
be down-regulated for either HIV or HCV versus HH,
covering the metabolism of carbohydrate, lipid, amino
acid, and nucleotide (Additional file 4). For genetic infor-
mation processing, pathways involved in DNA recombin-
ation and repair, tRNA biosynthesis, and proteasome were
all identified in the comparison of HCV versus HH, and
sporadically in other comparisons. For human diseases,
the majority of the pathways across the comparisons were
related to infection and/or immune system dysfunction,
and the renal cell carcinoma pathway was significantly al-
tered in the comparison of HCV versus HH (FDR =
0.036). The aforementioned pathways with high relevance
of HIV, HCV mono- and co-infection diseases were then
under further inspection.
Differential regulation of cytotoxicity pathway across 3
pairwise comparisons of patients
The NK cell mediated cytotoxicity pathway was up-
regulated in HH versus either HIV (FDR = 0.018) or HCV
(FDR < 0.001), and in HIV versus HCV (FDR= 0.019). In
the comparisons of HH versus HIV or HCV, 37 and 38
out of 134 gene members of this pathway were core
enrichment genes, respectively, as shown in the enrich-
ment plots and the heatmaps (Table 2; Figure 2). Be-
tween these 2 sets of core genes, 25 were present in
both comparisons (Figure 3), which included 15 genes
encoding for cell receptors (inhibitory receptors: KIR2DL1,
KIR2DL3, KIR2DL4, KIR2DL5A, KIR3DL1, and KIR3DL2;
activating receptors: KIR2DS1, KIR2DS5, KLRC2-CD94/
NKG2C-KLRD1, NCR3/NKp30, ITGAL/CD11a and its
ligand ICAM2; interferon receptor 1 IFNAR1; and TNF-
related apoptosis-inducing ligand TNFSF10/TRAIL), 8
genes involved in signaling cascade (kinases: PTK2B/Pyk-2,
ZAP70, MAPK1/ERK2 and phosphatase PTPN6/SHP-1;
PLC1/PLCγ mediating the production of DAG and IP3;
guanine nucleotide exchange factor VAV3; SH2 domain
containing 1B SH2D1B/EAT-2; and transcriptional fac-
tor NFATC3), and 2 genes encoding for effectors (PRF1/
perforin and GZMB/granzyme). The significant up-
regulation of cytotoxicity pathway in HIV versus HCV was
contributed by 32 core genes, also covering the genes en-
coding for cell receptors, signaling cascade, and effectors
(Table 2). Across all the 3 comparisons, 8 core genes were
common (KIR2DL3, KIR2DL5A, KIR2DL1, KIR3DL2,
KLRD1, TNFSF10, VAV3, and GZMB).
Down-regulation of cytokine-cytokine receptor pathway
in HIV/HCV co-infection
The cytokine-cytokine receptor interaction pathway was
significantly down-regulated in HH versus either HCV
(FDR = 0.003) or HIV (FDR = 0.028; Table 2; Figure 4).
Sixty-eight and 49 out of 262 gene members of this path-
way were coordinately down-regulated in co-infection
Table 2 Core genes contributing to the differential regulation of the critical pathways between HIV, HCV mono- and
co-infection identified by GSEA
Pathway Comparison Direction Size NOM
p-val
FDR Core enrichment genes
KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY HIVvsHH HH-up 134 0.000 0.018 HLA-G, SHC1, TNFSF10, VAV1, MAP2K2,
RAC2, PAK1, KLRD1, VAV3, KLRC2, LCK,
PLCG1, PIK3CD, KIR2DS1, PTPN6, PPP3CB,
SH2D1B, GZMB, FYN, ICAM2, ITGAL, NCR3,
KIR2DL3, ZAP70, MAPK1, PTK2B, PRKCA,
NFATC3, KIR2DL4, IFNAR1, PPP3CA,
KIR3DL2, KIR2DS5, KIR2DL5A, KIR3DL1,
KIR2DL1, PRF1
KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY HCVvsHH HH-up 134 0.000 0.000 ZAP70, PLCG1, SHC3, ICAM2, PIK3R2, HCST,
SH2D1A, KLRC1, SH2D1B, KIR2DS4,
KIR2DS1, NCR3, KLRC2, KIR2DS3, PTK2B,
NCR1, NFATC3, ITGAL, MAPK1, TNFSF10,
PTPN6, FASLG, IFNG, CD244, KIR2DL4,
IFNAR1, KIR2DS5, KIR2DL3, HLA-C, VAV3,
KLRD1, KLRC3, GZMB, KIR3DL1, KIR3DL2,
KIR2DL5A, PRF1, KIR2DL1
KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY HIVvsHCV HIV-up 134 0.000 0.019 IFNG, HLA-C, KLRC3, IFNB1, TNF, KLRD1,
CD244, FASLG, GZMB, VAV3, SH3BP2,
SH2D1A, NCR1, CASP3, GRB2, KIR2DS4,
HRAS, TNFSF10, KIR3DL2, FAS, HCST,
KIR2DL5A, PIK3R2, KRAS, IFNGR2, KIR2DL3,
VAV2, SOS2, BID, ULBP1, KIR2DL1, KIR2DS3
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION HIVvsHH HIV-up 262 0.000 0.028 IL6, OSM, CCL3L1, CCL3, IL1B, CCL2, IL8,
CXCL2, CCL3L3, TNF, TNFSF9, IFNG, IL1A,
CCL20, CCL4L1, CXCL16, CLCF1, IFNB1,
VEGFA, CCL28, CCL7, CCL4L2, IL12A,
CXCL1, IL23A, CD70, CXCR3, TNFRSF21,
TNFRSF9, IL28RA, CD40, TNFRSF13C, IL21R,
IFNGR1, TNFRSF4, CD40LG, IL12RB1, CXCR4,
IL15, IFNGR2, LTA, EPOR, CXCL9, FAS,
CXCR5, IL10RA, FLT4, PRLR, CCL8
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION HCVvsHH HCV-up 262 0.000 0.003 OSM, IL6, CXCL2, CCL20, IL1B, IL8, CD40LG,
IL1A, VEGFA, CCL3, CCL3L1, CCR4, CXCL1,
CXCR5, IL23A, CCL3L3, CXCL16, CXCR4,
TNFSF9, TNFRSF4, PRLR, TNFRSF13C, KIT,
CXCR3, CXCL6, XCR1, CXCR6, LTA, IL10RA,
IFNK, CX3CL1, IL1R2, TNFRSF25, IFNGR1,
CLCF1, TNFRSF10A, TNF, CCL28, IL2RA,
IL28A, TGFBR2, IL6ST, TGFB3, TNFSF13,
FLT3LG, IFNA10, TNFRSF21, CD70, PDGFRA,
IL24, CXCL13, TSLP, TNFRSF10C, TNFRSF9,
PDGFB, TGFB2, IFNA4, TNFSF4, CCR3, XCL2,
EDA, IFNA8, IL7R, IL13RA1, IL4R, CCL7,
IFNAR2, TNFSF12
KEGG_CELL_CYCLE HIVvsHCV HIV-up 115 0.000 0.016 PTTG1, MCM2, GADD45G, TFDP2, CDC20,
CCNE2, CDC16, CDK7, CCNB2, FZR1, MCM4,
CDK6, E2F5, WEE1, CCNE1, ANAPC10, TTK,
CDC23, ANAPC4, E2F3, MDM2, CDKN2C,
BUB1, CDKN2A, CCND1, MAD2L1,
ANAPC11, MCM7, YWHAQ, CDC27, CHEK1,
TGFB1, GADD45B
KEGG_WNT_SIGNALING_PATHWAY HIVvsHCV HCV-up 148 0.000 0.006 WNT5B, NFAT5, CSNK1A1L, CTNNBIP1,
CSNK2A2, CUL1, CAMK2A, PLCB1, WNT10A,
FZD7, PPP3R1, EP300, PPP3CB, NLK, FOSL1,
LRP5, FBXW11, SMAD3, PPP2R1A, DAAM1,
TBL1XR1, CAMK2G, DVL2, PLCB2, JUN,
PPP3CA, PRICKLE2, SIAH1, TCF7, FZD2,
LEF1, AXIN2, PPARD, PRKCA, PRKACG,
WNT7A
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Table 2 Core genes contributing to the differential regulation of the critical pathways between HIV, HCV mono- and
co-infection identified by GSEA (Continued)
KEGG_P53_SIGNALING_PATHWAY HIVvsHH HIV-up 67 0.004 0.029 SESN3, CDKN1A, GADD45A, THBS1,
PMAIP1, CCNG2, SESN1, CASP9, CCNE1,
CCND1, GADD45B, CASP8, CHEK1, CCNE2,
CCNB2, FAS, MDM2, MDM4, BID, TP53I3,
EI24, CDKN2A, SESN2, RCHY1, SERPINE1,
CD82
KEGG_RENAL_CELL_CARCINOMA HCVvsHH HCV-up 70 0.000 0.036 JUN, VEGFA, HIF1A, EGLN1, GRB2, RAF1,
EPAS1, SLC2A1, TGFB3, PIK3CA, NRAS,
MAPK3, RAPGEF1, CUL2, PDGFB, TGFB2,
KRAS, CREBBP
Size: Gene set size (number of genes in a particular gene set); NOM p-val: nominal p value; FDR: false discovery rate.
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unique and common (n = 32) core genes derived from these
comparisons, which covered almost every cytokine receptor
family (e.g. G protein-coupled receptors including CXC, C,
CX3C, and CC subfamilies and interferon family).
Significant alteration of cell cycle and WNT pathways
between HIV and HCV
The cell cycle (FDR = 0.016) and WNT signaling (FDR =
0.006) pathways were significantly up- and down-regulated
in HIV versus HCV (Table 2), respectively. Thirty-three
out of 115 gene members of cell cycle pathway were coor-
dinately up-regulated in HIV (Table 2; Additional file 5),
which appeared to promote G1/S transition and induce
arrest in G2/M transition. Twelve genes were asso-
ciated with the promotion of G1/S transition (cyclin
and cyclin dependent kinase: CCND1, CCNE1, CCNE2,
CDK6, CDK7; transcription factors and the associated
partners: E2F3, E2F5, TFDP2; and mini-chromosome
maintenance (MCM) complex: MCM2, 4, 7), whereas only
2 genes were inhibitory (CDK inhibitors CDKN2A and
CDKN2C). Seven genes were engaged in G2/M transi-
tion with the majority negatively regulating the transi-
tion (cyclin CCNB2 for promotion, negative regulators
WEE1 and YWHAQ, genes associated with p53 signaling
including MDM2 and CHEK1, stress sensors GADD45B
and GADD45G). Twelve genes participated in the meta-
phase to anaphase transition (anaphase promoting com-
plex and the associated molecules: ANAPC4, 10, 11,
CDC16, 20, 23, 27, PTTG1/securin, FZR1/Cdh1; spindle
checkpoint related genes: MAD2L1/MAD2, BUB1, and
TTK/Mps1).
For WNT signaling pathway, 36 out of 148 gene mem-
bers were coordinately up-regulated in HCV (Table 2;
Figure 5). In addition to the genes encoding for receptors
and ligands (FZD2, FZD7, LRP5, WNT10A, WNT5B, and
WNT7A), the majority of the core genes populated the
arms of β-catenin signaling and the WNT Ca2+ signaling.
Nine genes were associated with the activation of β-
catenin-dependent transcription and the expression of the
targeted genes (DVL2, CSNK2A2/CK2, PRKACG/PKA,EP300/CBP, SMAD3, LEF1, TCF7, PPARD, FOSL1/fra-1,
JUN), whereas 8 genes were involved in the negative
regulation of this process (β-catenin phosphorylation
and degradation complexes: AXIN2 and CSNK1A1L/
CKIα, CUL1, FBXW11/β-TrCP, SIAH1, TBL1XR1/TBL1;
kinases: CTNNBIP1/ICAT and NLK). Along the arm of
WNT Ca2+ signaling, 9 core genes covering all the mole-
cules of this branch were detected.
Significant alteration of cancer-related signaling pathways
in HIV/HCV co-infection
Both p53 signaling (FDR = 0.029) and renal cell carcinoma
pathways (FDR = 0.036) were significantly down-regulated
in HH versus HIV and HCV, respectively. Twenty-six out
of 67 gene members of the p53 pathway were coordinately
down-regulated in the HH group (Table 2; Additional
file 6), which included 4 genes interacting with p53
(CHEK1, MDM2, MDM4, and CDKN2A/p14arf ), 8
genes encoding for the arm of cell cycle arrest (cyclins:
CCNB2, CCND1, CCNE1, CCNE2; Cyclin-CDK inhibitor
CDKN1A/p21; stress sensors: GADD45A and GADD45B),
and 7 genes involved in apoptosis (BID, CASP8, CASP9,
EI24/PIGs, TP53I3/PIGs, PMAIP1/Noxa, FAS). The remai-
ning core genes spread along the branches of inhibition of
angiogenesis (SERPINE1/PAI, CD82/KAI, THBS1/TSP1),
DNA repair and damage prevention (SESN1, 2, 3), and p53
negative feedback (CCNG2 and RCHY1). It was also noted
that there was a trend in the down-regulation of p53
signaling in HCV versus HIV (FDR = 0.12), which was con-
tributed by 25 core genes. The spread of these core genes
in p53 pathway displayed a similar pattern to that observed
in the comparison between HIV and HH (see Additional
file 6 for common and distinct core genes detected in these
2 comparisons).
As for renal cell carcinoma pathway, 18 out of 70
gene members of the pathway were coordinately
down-regulated in the HH group (Table 2; Additional
file 7), which were featured by the genes encoding for
several growth factors (TGFB2, TGFB3, VEGFA, PDGFB)
and genes involved in cell survival and proliferation
(GRB2-KRAS/NRAS-RAF1-MAPK3/ERK-JUN/AP1 leading
Figure 2 Enrichment plot and heatmap for NK cell mediated cytotoxicity pathway detected by GSEA. A. Enrichment plot for the comparison
of HCV versus HH and the corresponding heat map of the core enrichment genes. Enrichment plot: Bottom, plot of the ranked list of all genes. Y axis,
value of the ranking metric; X axis, the rank for all genes. Genes whose expression levels are most closely associated with the HCV or HH group get the
highest metric scores with positive or negative sign, and are located at the left or right edge of the list. Middle, the location of genes from the
cytotoxicity pathway within the ranked list. Top, the running enrichment score for the gene set as the analysis walks along the ranked list. The score at
the peak of the plot is the enrichment score (ES) for this gene set and those genes appear before or at the peak are defined as core enrichment genes
for this gene set. Heat map: The genes that contribute most to the ES, i.e., genes that appear in the ranked list before or at the peak point of ES, are
defined as core enrichment genes. Rows, genes; columns, samples. Range of colors (red to blue) shows the range of expression values (high to low).
B. Enrichment plot for the comparison of HIV versus HH and the corresponding heat map of the core enrichment genes.
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cell survival).
qPCR confirmation of altered gene expression detected
by microarray
To further confirm the altered gene expression detected by
microarray analysis, mRNA expression levels of the selectedDEGs/core genes were measured by quantitative PCR
(qPCR; Table 3). The genes were selected based on the co-
verage of different levels and directions of fold change, dif-
ferent group comparisons, and/or biological significance.
The fold changes for each pairwise comparison evaluated by
qPCR were consistent with the results obtained from micro-
array, which confirmed the reliability of our microarray data.
Figure 3 Coordinately up-regulated genes of NK cell mediated cytotoxicity pathway in HH versus either HCV or HIV. The pathway figure
is adapted from Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/). The red and blue front colors highlight the
proteins encoded by the coordinately up-regulated genes in HH versus HIV and HCV, respectively. The background color filled with pink
highlights the proteins encoded by the commonly up-regulated genes found in both comparisons (HH versus HIV and HH versus HCV).
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Our study has investigated the transcriptome distinctions
of PBMCs from HIV, HCV mono- and co-infected pa-
tients (Additional file 1). Pairwise comparisons (HCV ver-
sus HH, HIV versus HH, and HIV versus HCV) were
carried out and differentially expressed genes as well as
significantly altered pathways were identified (Table 1;
Additional files 3 and 4). Across the DEG lists, immune
system and metabolic processes were the major biological
themes derived from the DEGs. At the pathway level,
GSEA identified a panel of significantly altered pathways
for each pairwise comparison, which could be divided into
the following five biological categories: (1) immune sys-
tem; (2) signaling transduction and cell cycle; (3) metabol-
ism; (4) genetic information processing; and (5) human
diseases (Additional file 4). As GSEA enabled a morecomprehensive detection of genes contributing to the en-
richment of the pathways correlated with specific patient
groups, the subsequent discussion will focus on the path-
ways significantly associated with each infection group re-
vealed by GSEA. Since the first three categories had the
most direct relevance to HIV disease and HCV-mediated
carcinogenesis, our subsequent discussion shall center on
the crucial pathways from these categories, including cyto-
toxicity, cytokine-cytokine receptor interaction, cell cycle,
WNT, and p53 signaling pathways (Table 2).
Under the category of immune system, the most unique
finding in our study is the significant up-regulation of
cytotoxicity pathway in the former versus the latter group
across the 3 pairwise comparisons (HH versus HIV, HH
versus HCV, HIV versus HCV; FDR from <0.001 to 0.019;
Figure 3; Table 2). Our study is the first to report the
Figure 4 Coordinately down-regulated genes of cytokine-cytokine receptor pathway in HH versus either HIV or HCV. The pathway
figure is adapted from Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/). The red and blue front colors highlight
the proteins encoded by the coordinately down-regulated genes in HH versus HIV and HCV, respectively. The background color filled with pink
highlights the proteins encoded by the commonly down-regulated genes found in both comparisons (HH versus HIV and HH versus HCV).
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tween HIV, HCV mono- and co-infection, which is also
supported by previous findings in HIV/HCV co-infection
[30,31,33,34]. Recently, two PBMC studies have implicated
this pathway. One of them reported its enrichment in the
significantly up-regulated genes in co-infected patients
versus controls [34], and the other showed NK cell signal-
ing in the expanded network constructed from the gene
signature in HH versus HCV group [30]. In addition, the
up-regulation of cytotoxicity pathway in HH versus HIV
as well as in HIV versus HCV has been found in CD4+ T
cells [31], and high percentages of cytotoxic CD8+ T cells
associated with liver fibrosis in co-infected patients have
been detected by the flow cytometry study [33].
Notably, a substantial portion of the core genes contrib-
uting to the significant regulation of cytotoxicity pathway
encoded for killer-cell immunoglobulin-like receptors
(KIRs) (Table 2). Among the 8 core genes present across 3
pairwise comparisons, 4 genes encoded for KIRs (KIR2DL1,
KIR2DL3, KIR2DL5A, and KIR3DL2), which may implicate
that the KIRs, with their crucial roles in virus infection,
were under such tight regulations that their expression
levels were able to reflect specific patterns of particularvirus-host interactions. This speculation was in line with
the previous study in which it was found that elevated fre-
quencies of NK cells expressing HLA-C binding KIRs, such
as the aforementioned KIR2DL1 and KIR2DL3, were asso-
ciated with HCV clearance [35]. Moreover, the KIR2DL3:
HLA-C1 homozygosity had the protective effects in HCV-
infected individuals exposed to low inocula [36], possibly
due to their lower avidity interactions that resulted in an
advantageous activation of NK cell against HCV. The simi-
lar mechanism has also been proposed for the observation
that resistance to HIV infection was associated with
KIR3DL1 homozygosity in the absence of its ligand HLA-
Bw4 in an African cohort [37]. Interestingly, KIR3DL1 was
also detected as one of the coordinately up-regulated core
genes in HH versus either HIV or HCV in this study
(Figure 3). Besides KIRs, 5 up-regulated core genes encod-
ing for activation receptors were also present in HH versus
either HCV or HIV, of which NCR3/NKp30 was note-
worthy. The increased expression of NKp30 was protective
against HCV infection in high-risk individuals and inhibited
HCV replication in vitro [38]. In HIV/HCV co-infected in-
dividuals, a significantly higher proportion of NK cells ex-
pressing NKp30 on their surface were detected compared
Figure 5 Coordinately up-regulated genes of WNT signaling pathway in HCV versus HIV. The pathway figure is adapted from Kyoto
Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/). The proteins encoded by the coordinately up-regulated genes in the
HCV group are highlighted in red.
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aforementioned core genes played protective roles against
virus infection and the cytotoxicity function was impaired
in HIV and HCV infection [39-41], the up-regulation of the
cytotoxicity pathway in co-infection would be most likely
to reflect a compensatory effect of the cytotoxic cells im-
posed by aberrant activation or anergy arising from the co-
infection.
Another prominent change observed in the immune
system was the down-regulation of cytokine-cytokine re-
ceptor interaction pathway in HH versus either HCV or
HIV (Table 2; Figure 4). For the core genes commonly
down-regulated in HH in both comparisons, some of
them were previously reported with decreased expression
in HH versus HCV, such as IL8 and TNF-α [25,26,28]. For
the core genes uniquely detected in one of the two
comparisons, the coordinate down-regulation of IFNG,
IFNGR2 and FAS was pronounced only in HH versus
HIV, whereas the coordinate down-regulation of CX3CL1,
interferon-α genes (IFNA4, 8, 10 and IFNAR2) and TGF-β
genes (TGFB2, 3, and TGFBR2) was observed only in HHversus HCV. While the exact mechanisms underlying
these distinct immune activation profiles are not well
understood, previous studies have suggested some crucial
roles of these genes, such as the elevation of CX3CL1 as a
marker of liver fibrosis/injury [29], TGF-β as a potent in-
ducer of fibrogenesis [26], and interferon-α inhibiting
HCV replication [42]. Interestingly, a recent study has re-
ported that an effective interferon-γ mediated inhibition
of HCV replication by NK cells is associated with spontan-
eous clearance of HCV in HIV+ patients [43], which is in
line with our simultaneous detections of both the dysregu-
lation of NK cytotoxicity pathway and the decreased ex-
pression of IFNG in co-infected individuals.
For signaling transduction and cell cycle pathways, the
respective up- and down-regulation of cell cycle and
WNT signaling pathways in HIV versus HCV were
noted, which may reflect the differential impact of these
two viruses on cell proliferation. While the genes in-
volved in the promotion of G1/S transition and the in-
duction of arrest in G2/M transition were up-regulated
in the HIV group (Additional file 5), the activation of cell
Table 3 qPCR confirmation of altered gene expression detected by microarray






IL6 Cytokine- cytokine receptor interaction; HIF-1
signaling; FOXO signaling; PI3K-Akt signaling;
Toll-like receptor signaling
HIVvsHH 5.1 4.8
IL6 HIVvsCTR 4.6 3.5
CXCR4 Cytokine-cytokine receptor interaction;
Chemokine signaling; Endocytosis; Axon
guidance; Leukocyte transendothelial migration
HCVvsCTR −1.5 −2.5
TAOK1 MAPK signaling pathway HCVvsHH −2.0 −3.7
TAOK1 HIVvsHH −2.2 −2.3
EGR2 Hepatitis B; HTLV-I infection; Viral carcinogenesis HCVvsHH 8.8 10.2
EGR2 HIVvsHH 8.8 9.3
PPP3CB MAPK signaling; WNT signaling; Apoptosis;
Calcium signaling
HHvsCTR 1.8 1.4
WNT7A WNT signaling; Hedgehog signaling; Hippo
signaling; HTLV-I infection
HCVvsHH 2.1 2.6
DUSP2 MAPK signaling pathway HCVvsHH 2.6 2.8
DUSP2 HIVvsHH 2.1 2.7
DUSP2 HCVvsCTR 2.5 3.2
MCM2 DNA replication; Cell cycle HCVvsHH −1.5 −2.9
MCM2 HIVvsHCV 1.5 1.9
GZMB NK cell mediated cytotoxicity; Regulation of
actin cytoskeleton; Transcriptional misregulation
in cancer; Autoimmune thyroid disease
HCVvsHH −2.4 −3.1
GZMB HIVvsHH −1.5 −2.0
GZMB HIVvsHCV 1.6 1.6
KLRD1 NK cell mediated cytotoxicity pathway;
Antigen processing and presentation;
Graft-versus-host disease
HCVvsHH −2.2 −2.9
KLRD1 HIVvsHH −1.3 −1.5
KLRD1 HIVvsHCV 1.6 2.0
WEE1 Cell cycle HIVvsHCV 1.3 1.9
SESN1 p53 signaling HIVvsHH 1.6 2.1
Fold change by qPCR was obtained from the mean expressions of the tested genes in each group. All values represent fold changes between expression levels of
the first group versus expression levels of the second group. Minus sign indicates down-regulation in the first group whereas positive sign indicates up-regulation
in the first group. Housekeeping gene GAPDH was used as an internal control and the normalizer in qPCR.
Genes in Italic font indicate the core genes detected by GSEA.
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the HCV group (Figure 5). Consistently, the differential
regulation of cell cycle between HIV and HCV was also
prominent in microarray studies on CD8+ and CD4+ T
cells, and the similar pattern of up-regulation of genes in-
volved in promotion of G1/S transition along with G2 ar-
rest was also detected in CD4+ T cells in HIV versus HCV
[31,32]. Taken together, these observations could possibly
suggest that HCV-infected cells may experience cell cycle
dysregulation at a less severe level than HIV-infected cells.
In support of this speculation, a recent study has shown
that T cells in HIV/HCV co-infected patients were
destroyed at a slower rate than in HIV mono-infected pa-
tients [44]. In addition, previous studies have demon-
strated the oncogenic activity of HCV core protein, which
induces cell proliferation through various processes such
as activating RB/E2F signaling [45,46]. However, therewere also some discrepant results [47,48], which could be
attributed to the variations in the cohort and different cell
systems (in vivo versus in vitro).
As for the oncogenic activity of HCV proteins, it was not
only evident in the up-regulation of WNT pathway in
HCV versus HIV, but also manifested by the down-
regulation of p53 signaling pathway in HH versus HIV. For
WNT signaling pathway, the up-regulation of FZD7 re-
ceptors associated with the activation of the WNT/beta-
catenin pathway, which was observed in this study in HCV
versus HIV (Figure 5), was a common molecular event
in HCC [49]. The up-regulation of PPARD (peroxisome
proliferator-activated receptor, a central regulator of trigly-
ceride homeostasis) in WNT/beta-catenin pathway was
also detected in this study. The persistent activation of
PPAR was essential for the pathogenesis of hepatic steatosis
and HCC induced by HCV infection in the animal model
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cell cycle arrest, apoptosis, inhibition of angiogenesis, DNA
repair and damage prevention, were all coordinately down-
regulated in HH versus HIV (Additional file 6), which may
contribute to HCV-induced carcinogenesis. Interestingly,
there was also a trend in the down-regulation of p53 path-
way in HCV versus HIV (FDR = 0.12), and the core genes
detected in this comparison displayed a similar pattern to
that observed in the comparison between HIV and HH
(Additional file 6). Hence, it is possible that this gene ex-
pression signature may reflect a specific pattern directly re-
lated to the oncogenic activity of HCV proteins. These
observations were also consistent with previous studies
showing that p53 effector function could be compromised
by the functional inactivation of tumor suppressor protein
promyelocytic leukemia through the HCV core protein in
HCV-infected cells [51], and that the NS3 protein could
form complexes with p53 and repress its function [52].
Among the pathways of human diseases, the onco-
genic role of HCV was further highlighted by the up-
regulation of renal cell carcinoma pathway in HCV
versus HH (Additional file 7). Notable was the up-
regulation of HIF-α (EPAS1 and HIF1A), which led to the
up-regulation of growth factors (TGFB2, TGFB3, VEGFA,
PDGFB) and glucose transporter SLC2A1/GLUT1. Previ-
ous studies have shown that the expression of HCV pro-
tein activates HIF-1 by normoxic stabilization of its α
subunit (HIF-α), resulting in increased expression of HIF-
controlled genes, many of which are involved in tumor
growth and metastasis, such as VEGF and TGF-β [53-55].
It was also noted that metabolic pathways, particularly
those involved in energy metabolism such as oxidative
phosphorylation (OXPHOS) and TCA cycle, were consist-
ently up-regulated in HH versus either HIV or HCV
(Additional file 4). Similarly, gene sets including carbohy-
drate, lipid, amino acid, and nucleotide metabolism were
also up-regulated in the co-infection group in CD4+ T
cells [31]. This up-regulation in HH may implicate a com-
pensatory event at a higher level than in mono-infection,
possibly arising from more insufficient energy supply due
to the more severe OXPHOS impairment imposed by
both HIV and HCV [55,56]. For genetic information pro-
cessing, all the pathways were up-regulated in HH versus
either HIV or HCV, which involved processes at the DNA
level including recombination, repair, and replication, and
at translational or posttranslational level including tRNA
synthesis and proteasome (Additional file 4), implying the
more severely perturbed human gene machinery in HIV/
HCV co-infection.
A few limitations of this study should be noted. First,
our data from PBMCs only provided the overall changes
of the transcriptomes in circulating mononuclear cells. A
more thorough understanding of the mechanisms under-
lying these changes would require further transcriptomeprofiling at the individual cell type level, as we previously
did on monocytes and T cell subsets [56-58]. Secondly, al-
though our results pinned down to important KIR genes
such as KIR2DL3 and KIR3DL1, the genotype of HLA was
not available and the sample size also limited further ana-
lysis of genotype association. Thirdly, this study used a
relatively small sample size appropriate for the pilot inves-
tigation. Future studies using larger sample size are thus
warranted to confirm the results as well as to explore the
role of KIRs and HLA genotype in co-infection. Finally,
although the GSEA identified a panel of significantly al-
tered pathways differentiating between HIV, HCV
mono- and co-infection, the predictive nature of GSEA
as the common limitation of statistical tools should be
noted. Future biological experiments focusing on the
clinically and pathologically relevant pathways shall be
carried out, which can not only further validate the
novel use of PBMCs, but also provide more incisive
mechanistic insights in HIV/HCV co-infection.
Methods
Study subjects
Blood samples (8–10 ml in EDTA) were obtained by
venipuncture from 27 subjects belonging to the following
clinical groups: HCV infected patients (n = 5), HIV in-
fected patients (n = 7), HIV/HCV co-infected patients (n =
10), and HIV/HCV sero-negative healthy controls (n = 5;
Additional file 1). The co-infected patients were from
Hospital Carlos, Madrid, Spain, and the rest were from
Westmead Hospital, Sydney. Institutional Ethics Committee
of the Hospital Carlos, Madrid, Spain, independently
approved the use of the co-infected samples, and all the
other blood samples were collected after individual in-
formed written consent using a protocol approved by
the Sydney West Area Health Services Research Ethics
Committee.
Isolation of PBMCs and RNA extraction
PBMCs were extracted immediately after the collection
of whole blood using Ficoll-hypaque density gradient
centrifugation [59]. Total RNA was isolated from puri-
fied cells using RNeasy Mini kit (Qiagen Pty Ltd., Clifton
Hill, Victoria, Australia) with an integrated step of on-
column DNase treatment.
cRNA preparation, microarray hybridization and scanning
RNA quality was checked by Agilent Bioanalyzer and RNA
Integrity Scores were higher than 7 for all the samples.
cRNA amplification and labeling with biotin were per-
formed using Illumina TotalPrep RNA amplification kit
(Ambion, Inc., Austin, USA) with 250 ng total RNA as in-
put material. cRNA yields were quantified with Agilent
Bioanalyzer and 750 ng cRNAs were hybridized to Illumina
HumanHT-12 v3 Expression BeadChips (Illumina, Inc.,
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array contained >48,000 gene transcripts, of which, 46,000
were derived from human genes in the National Center for
Biotechnology Information (NCBI) Reference Sequence
(RefSeq) and UniGene databases. All reagents and equip-
ment used for hybridization were purchased from Illumina,
Inc. According to the manufacturer’s protocol, cRNAs
were hybridized to arrays for 16 hours at 58°C before being
washed and stained with streptavidin-Cy3. Then the bead-
chips were centrifuged to dry and scanned on the Illumina
BeadArray Reader confocal scanner. To minimize the
batch effect, the microarray chips were all processed at the
single site using the same platform with the identical set-
ting of the parameters by the same experimenter.
Analysis of differentially expressed genes
The quality of the entire data set was assessed by box plot
and density plot of bead intensities, density plot of coeffi-
cient of variance, pairwise MAplot, pairwise plot with
microarray correlation, cluster dendrogram, and non-
metric multidimensional scaling using R/Bioconductor and
the lumi package [60]. Based on the quality assessment, all
27 samples were deemed suitable for further analysis. Data
normalization was performed using log2 transform and a
robust spline normalization (RSN) implemented in the
lumi package for R/Bioconductor [60,61]. To reduce false
positives of differentially expressed genes, genes below de-
tectable limit (based on a detection p value cut-off 0.01)
were removed from the dataset. A linear model fit in con-
junction with an empirical Bayes statistics was used to
identify candidate DEGs [62]. P values were corrected for
multiple testing using FDR adjustment. Each patient group
was first compared to the control group and we then fo-
cused on pairwise comparisons between the 3 patients
groups. Candidate DEGs with fold change >1.5 and FDR <
0.05 were identified for each of the comparisons. The
heatmap including all the study subjects was produced by
heatmap.2 function of the gplots package from R/Biocon-
ductor. The lists of the DEGs derived from the pairwise
comparisons between the patients groups were submit-
ted to PANTHER classification system for categorizing
the DEGs based on biological processes defined by GO
terms [63,64].
Gene set enrichment analysis
GSEA was used for the investigation of global dysregula-
tions of the biological pathways between the 3 patients
groups. The gene sets were from MsigDB [65], catalog
C2 functional sets, subcatalog KEGG pathways, which
included 186 gene sets from pathway databases. For each
group comparison, GSEA was performed using the nor-
malized data of the entire 48,803 transcripts (GSEA ver-
sion 2.0.14, Broad Institute http://www.broad.mit.edu/
gsea). First, a ranked list was obtained by ranking allgenes according to the correlation between their expres-
sion and the group distinction using the metric signal to
noise ratio. Then the association between a given gene
set and the group was measured by the non-parametric
running sum statistic termed the enrichment score (ES),
which was calculated by walking down the ranked list
(increasing ES when encountering a gene in the given
gene set and decreasing ES when encountering a gene
not in the gene set). To estimate the statistical signifi-
cance of the ES, a nominal p value was calculated by
permuting the genes 1,000 times. To adjust for multiple
hypothesis testing, the maximum ES was normalized to
account for the gene set size (NES) and the FDR corre-
sponding to each NES was also calculated. Along with
the pathway enrichment results, the details report for
each significant pathway was simultaneously generated.
This report has listed the details of each gene member
in columns, one of which indicates whether this gene
member is “core enrichment gene” or not. The core en-
richment genes account for the enrichment signal of the
pathway and the inspection of them can reveal a bio-
logically important subset within the pathway [65].
Real-time quantitative PCR
Twelve genes were selected for validation based on the
coverage of different levels and directions of fold change,
different group comparisons, and/or biological signifi-
cance. Purified total cellular RNA was used for reverse
transcription with oligo d(T) and Superscript III followed
by RNase H treatment (Invitrogen Life Technologies). The
cDNA was then subjected to qPCR in a 96-well format in
triplicate reactions with defined primers and SYBR Green
(Invitrogen Life Technologies). The qPCR reactions were
carried out using Mx3005P™ QPCR System (Stratagene).
The mean expressions of the tested genes in each group
were obtained and the housekeeping gene GAPDH was
used as an internal control and the normalizer for all data.
The fold change was calculated by the relative quantitation
method 2-(ddCt). Primer sequences for each transcript are
available from the authors upon request.
Conclusions
Our study is the first to identify the differential regulation
of cytotoxicity pathway discriminating between HIV, HCV
mono- and co-infection, which may reflect the distinct
patterns of virus-host cell interactions underlying disease
progression. Further inspection of cytotoxicity pathway
has pinned down to the expression of the KIR genes to be
associated with specific patterns of particular virus-host
interactions. Moreover, the down-regulation of cytokine-
cytokine receptor interaction and the up-regulation of
metabolic pathways in HH versus HIV or HCV reflected
aberrant immune activation and more severely perturbed
metabolism in the co-infection. Between HIV and HCV,
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pathways may suggest the distinct impact of HIV and
HCV on cell proliferation and differentiation. In addition,
the up-regulation of WNT and retinal carcinoma path-
ways in HCV (versus HIV and HH, respectively) may indi-
cate the oncogenic role of this virus. This oncogenic role
was further manifested by the down-regulation of the
components of p53 pathway in HH versus HIV, consisting
of inhibition of angiogenesis as well as DNA repair and
damage prevention. Future studies on the regulation of
these pathways and the corresponding core enrichment
genes may provide a detailed understanding of the mo-
lecular mechanisms involved, which may also aid the de-
velopment of therapeutic interventions.Additional files
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